Paper Details

  1. Home
  2. Paper Details

[Clinical Practice of <sup>177</sup>Lu-DOTATATE in the Treatment of Neuroendocrine Tumors].

Author: ChenYue, DengYing, HeLi-Meng, LiuNan, WangAn-Bo, YanXue-Xian, ZhangWei

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article discusses the selection, preparation, and management of patients undergoing peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). PRRT is a promising treatment option for NETs, which often overexpress somatostatin receptors (SSTRs). This article provides a comprehensive overview of PRRT, including patient selection criteria, pre-treatment medications, administration methods, treatment cycles, side effects, follow-up plans, and potential combinations with other drugs. This article aims to equip healthcare professionals with the knowledge and tools to effectively utilize PRRT in clinical practice.
Paper Details　
Original Abstract of the Article :
Most of the neuroendocrine tumors(NETs) overexpress the somatostatin receptor(SSTR),which provides a reliable target for SSTR-targeted peptide receptor radionuclide therapy(PRRT).Compared with drug therapy,PRRT has high objective response rate and significantly prolongs patients' survival.Moreover,t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3881/j.issn.1000-503X.14463

データ提供：米国国立医学図書館（NLM）

177Lu-DOTATATE: A Powerful Tool in the Treatment of Neuroendocrine Tumors

This article provides a comprehensive overview of the clinical practice of 177Lu-DOTATATE in the treatment of neuroendocrine tumors (NETs). The article highlights the significant role of peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE in the management of NETs, which often overexpress somatostatin receptors (SSTRs). The article emphasizes the high objective response rates and prolonged survival observed with PRRT compared to drug therapy. The article also provides practical guidance for patient selection, pre-treatment medication, administration methods, treatment cycles, and potential side effects, offering a valuable resource for healthcare professionals involved in the management of NETs.

Harnessing the Power of Targeted Therapy in NETs

This article sheds light on the significant advancements in the treatment of NETs with PRRT using 177Lu-DOTATATE. The article emphasizes the potential benefits of this targeted therapy, which specifically targets SSTR-overexpressing NETs. This approach, much like a camel navigating the desert using landmarks, focuses on a specific target to achieve a desired outcome. The article's comprehensive overview provides valuable guidance for healthcare professionals in implementing this promising therapy.

Understanding NETs and Treatment Options

As a healthcare professional, I recognize the importance of staying abreast of the latest advancements in the treatment of NETs. This article offers a valuable resource for understanding the clinical application of PRRT using 177Lu-DOTATATE. It highlights the potential benefits and challenges associated with this therapy, providing a framework for making informed decisions about the best treatment approach for individual patients. It's a reminder that, like a camel navigating a vast and complex desert, we must continually seek new knowledge and explore innovative solutions to improve the lives of our patients.

Dr. Camel's Conclusion

This article provides a comprehensive overview of the clinical practice of 177Lu-DOTATATE in the treatment of NETs, highlighting the potential benefits and challenges of this innovative therapy. It's a reminder that the pursuit of effective treatments for cancer is a continuous journey, much like a camel traversing a vast desert, requiring dedication, perseverance, and a commitment to finding solutions.

Date :
  1. Date Completed 2023-01-11
  2. Date Revised 2023-01-11
Further Info :

Pubmed ID

36373637

DOI: Digital Object Identifier

10.3881/j.issn.1000-503X.14463

Related Literature

Article Analysis
・Side Effects of octreotide
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.